Clinical Trial Update: TGR1202 in Relapsed and Refractory Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for TGR1202 in relapsed/refractory follicular lymphoma; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• TGR1202

Snippet

Sponsor: Columbia University | Conditions: Follicular Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2021-07-16